Identification and Validation of Afatinib Potential Drug Resistance Gene BIRC5 in Non-Small Cell Lung Cancer
IntroductionResistance to second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), afatinib, is the most significant challenge in the clinical management of non-small cell lung cancer (NSCLC), and the underlying mechanisms remain unclear.MethodsGenomic signatures that...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Frontiers Media S.A.
2021-11-01
|
| 叢編: | Frontiers in Oncology |
| 主題: | |
| 在線閱讀: | https://www.frontiersin.org/articles/10.3389/fonc.2021.763035/full |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|